ReviewDrugs2021
Telitacicept: First Approval.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 149 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus
Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
The Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis: A Multicenter Clinical Study
Who cites it
149 citing papers in PubMed, 6 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Telitacicept in myasthenia gravis: a systematic review of clinical outcomes, steroid-sparing effects, and safety.Frontiers in neurology · 2026Pooled it
- CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review.Frontiers in immunology · 2026Pooled it
- Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.Frontiers in nutrition · 2026Pooled it
- Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies.Frontiers in medicine · 2026Pooled it
- Organ-based characterization of B cells in patients with systemic lupus erythematosus.Frontiers in immunology · 2025Pooled it
- Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.European journal of neurology · 2024Trial
- BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.Annals of the rheumatic diseases · 2023Trial
- Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.Clinical pharmacology in drug development · 2022Trial
- APRIL: spring forward also for IgA vasculitis nephritis in children.Pediatric nephrology (Berlin, Germany) · 2026Article
- B-cell landscape remodelling following dual BAFF/APRIL inhibition with telitacicept in lupus nephritis: extrafollicular axis clearance and its association with clinical response.Lupus science & medicine · 2026Article
- Comparative effectiveness and predictors of SRI-4 and LLDAS attainment in active systemic lupus erythematosus: a real-world study of telitacicept versus belimumab.Clinical rheumatology · 2026Observational
- Real-World Clinical Outcomes and Corticosteroid Tapering in Telitacicept-Based Therapy for Ocular Myasthenia Gravis: An Exploratory Analysis by Prior Treatment History.Brain and behavior · 2026Article
- Advances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic.Journal of internal medicine · 2026Review
- Observation on the short-term efficacy of telitacicept in the treatment of primary IgA nephropathy.International urology and nephrology · 2026Article
- Review
- Efficacy of telitacicept in a refractory systemic lupus erythematosus patient with lupus nephritis and subsequent pregnancy: a case-based review.Clinical rheumatology · 2026Review
- Molecular characterisation of telitacicept response phenotypes in systemic lupus erythematosus: an exploratory integrated transcriptome and B-cell receptor repertoire profiling study.Journal of translational medicine · 2026Article
- Tofacitinib versus BAFF inhibitor in mild to moderate systemic lupus erythematosus: a real-world study based on CSTAR cohort.Clinical rheumatology · 2026Article
- Efficacy and safety of telitacicept in IgA vasculitis nephritis: a single-center retrospective study.European journal of pediatrics · 2026Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telitacicept (Tai'ai
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.